Eledon Pharmaceuticals Inc
F:2TK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eledon Pharmaceuticals Inc
F:2TK
|
US |
|
A
|
Airport City Ltd
TASE:ARPT
|
IL |
|
S
|
Sagar Productions Ltd
BSE:532092
|
IN |
|
B
|
Bao Ngoc Investment Production Corp
VN:BNA
|
VN |
|
Al Yamamah Steel Industries Company CJSC
SAU:1304
|
SA |
|
Anadolu Efes Biracilik ve Malt Sanayii AS
IST:AEFES.E
|
TR |
|
E
|
ESGold Corp
F:N2W
|
CA |
|
Bigben Interactive SA
PAR:BIG
|
FR |
|
O
|
Ozyasar Tel ve Galvanizleme Sanayi AS
IST:OZYSR.E
|
TR |
|
C
|
Cangzhou Dahua Co Ltd
SSE:600230
|
CN |
|
E
|
Exprivia SpA
MIL:XPR
|
IT |
|
V
|
Via Transportation Inc
NYSE:VIA
|
US |
|
Value Golf Inc
TSE:3931
|
JP |
|
S
|
Silver One Resources Inc
LSE:0THK
|
CA |
|
P
|
PT Era Digital Media Tbk
IDX:AWAN
|
ID |
|
Century Therapeutics Inc
NASDAQ:IPSC
|
US |
|
B
|
Biofrontera AG
SWB:B8F
|
DE |
|
P
|
Pilkington Deutschland AG
F:FDD
|
DE |
|
T
|
Trillium Gold Mines Inc
OTC:TGLDF
|
CA |
|
C
|
Crazy Sports Group Ltd
HKEX:82
|
CN |
|
I
|
Infinico Metals
XTSX:INFM
|
CA |
|
A
|
Amarc Resources Ltd
OTC:AXREF
|
CA |
|
Turbo Energy SA
F:X8WA
|
ES |
|
C
|
CropEnergies AG
XBER:CE2
|
DE |
Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals is a clinical-stage drug company focused on medicines that calm the immune system. Its lead programs center on tegoprubart, an antibody designed to block a key immune signal called CD40L. The goal is to help patients who receive organ transplants or who live with autoimmune diseases by reducing harmful immune attacks without shutting the immune system down completely. The company does not sell a broad portfolio of approved drugs. Instead, it develops and tests experimental therapies and then looks for partners or future approvals that could turn those medicines into products. Its main customers, if its drugs reach the market, would be transplant centers, hospitals, and physicians treating patients who need long-term immune suppression. Eledon makes money today mainly through research and development activities tied to its drug pipeline, and in the future it would expect to earn product sales, licensing fees, or collaboration payments if any of its therapies succeed. What makes its business different is that it is trying to solve a very specific problem in transplant medicine: preventing rejection by targeting one immune pathway that could be less disruptive than older blanket immunosuppressive drugs.
Eledon Pharmaceuticals is a clinical-stage drug company focused on medicines that calm the immune system. Its lead programs center on tegoprubart, an antibody designed to block a key immune signal called CD40L. The goal is to help patients who receive organ transplants or who live with autoimmune diseases by reducing harmful immune attacks without shutting the immune system down completely.
The company does not sell a broad portfolio of approved drugs. Instead, it develops and tests experimental therapies and then looks for partners or future approvals that could turn those medicines into products. Its main customers, if its drugs reach the market, would be transplant centers, hospitals, and physicians treating patients who need long-term immune suppression.
Eledon makes money today mainly through research and development activities tied to its drug pipeline, and in the future it would expect to earn product sales, licensing fees, or collaboration payments if any of its therapies succeed. What makes its business different is that it is trying to solve a very specific problem in transplant medicine: preventing rejection by targeting one immune pathway that could be less disruptive than older blanket immunosuppressive drugs.
Strategic Focus: Eledon is now prioritizing its kidney transplantation program, aiming for Tegoprubart to become a new standard of care.
Encouraging Early Data: Phase 1b trial showed no acute rejection in initial patients and strong kidney function, with mean eGFRs above 70 up to week 31.
Phase 2 Trial Launch: The Phase 2 BESTOW trial in kidney transplantation is on track to start midyear, with 120 participants comparing Tegoprubart to tacrolimus.
Major Financing Secured: Eledon raised up to $185 million in private placement, with $35 million upfront, providing capital to fund clinical development.
Safety Profile: Tegoprubart showed good tolerability so far, with no serious adverse events reported across studies.
IgAN Program Deprioritized: The IgA nephropathy program is winding down, and associated spending will decrease in Q2 2023.
Financial Update: Net loss widened to $10.8 million for the quarter, with higher R&D expenses due to increased clinical activity.
